Work

Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease (gfx350, 2018)

FWCI:
Cites:
Cited by:
Related to: 10